managing-child-psychiatry

name	managing-child-psychiatry
description	Adapts psychiatric evaluation and treatment for pediatric patients with developmental considerations. Use when evaluating children psychiatrically, managing pediatric medications, or documenting child psychiatric assessments.
tags	["management","psychiatry","patient-care","treatment"]
metadata	{"author":"casemark","practice_areas":["Psychiatry","Psychology","Behavioral Health"],"document_types":["Management Report"],"skill_modes":["Management","Coordination"]}

Managing Child Psychiatry

Adapts psychiatric evaluation, diagnosis, and treatment for pediatric patients (ages 3-17) with developmental considerations, family systems integration, and AACAP Practice Parameter compliance.

Why This Skill Exists

Child and adolescent psychiatric disorders affect approximately 1 in 6 children (ages 2-8) and 1 in 5 adolescents, yet only 50% receive treatment. Psychiatric assessment of children differs fundamentally from adult assessment: children cannot reliably self-report symptoms, developmental context determines whether behaviors are normal or pathological, family dynamics are integral to both etiology and treatment, and medication dosing, FDA indications, and side-effect profiles differ from adult populations. The AACAP Practice Parameters provide disorder-specific guidelines for assessment and treatment of children and adolescents.

The medicolegal landscape in child psychiatry is complex. Informed consent must come from parents/guardians, while assent is obtained from the child. Confidentiality protections differ from adult practice — parents generally have access to treatment information for minor children, with exceptions for reproductive health and substance use in some states. Mandatory reporting obligations for child abuse and neglect are non-negotiable. Off-label prescribing is common in pediatric psychiatry (many psychotropics lack FDA approval for pediatric use) and requires specific documentation of rationale.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the child's age and developmental level? (chronological age, cognitive/emotional developmental level, grade in school) — default: obtain
2. Who is the referral source? (parent, school, pediatrician, court, child protective services) — default: identify
3. What is the legal custody arrangement? (biological parents, single parent, foster care, adoption, guardianship, DCFS ward) — default: verify legal consent authority
4. Who can provide consent for evaluation and treatment? — default: verify legal custodial parent/guardian
5. Is there a known or suspected history of abuse, neglect, or trauma? — default: screen (mandatory reporting obligations apply)
6. Is the child currently in school? What type of educational placement? (general education, IEP, 504, special school) — default: obtain school records
7. Has the child been previously evaluated? (psychiatric, psychological, neuropsychological, speech/language, occupational therapy) — default: obtain prior evaluations
8. What informants are available? (both parents, teachers, daycare providers, therapist, pediatrician) — default: multi-informant assessment required

Documents to Request

• Parent-completed developmental history questionnaire
• School records: report cards, IEP/504 documents, disciplinary records, teacher observations
• Prior psychiatric and psychological evaluations
• Pediatrician records including developmental screening results
• Standardized rating scales from parents and teachers (CBCL, Conners, Vanderbilt)
• Neuropsychological testing results if available
• Speech/language and occupational therapy evaluations if applicable
• Child protective services records if applicable
• Birth and perinatal records (for developmental concerns)
• Custody and legal documents (especially in foster care/adoption/divorce situations)

---

Step 1: Developmental History and Multi-Informant Assessment

Developmental History (obtained from parent/caregiver)

• Pregnancy: Planned/unplanned, complications, substance exposure, medications, infections, gestational age at birth
• Birth: Vaginal/C-section, birth weight, APGAR scores, NICU stay, birth complications
• Motor milestones: Sat independently (6-8 months), walked (12-15 months), fine motor development
• Language milestones: First words (12 months), two-word phrases (24 months), conversational speech (3 years)
• Social milestones: Social smile (2 months), stranger anxiety (8-10 months), joint attention (12-18 months), pretend play (18-24 months), cooperative play (3-4 years)
• Toilet training: Age achieved, difficulties, regression
• Temperament: Easy, difficult, slow-to-warm (Thomas & Chess)

Multi-Informant Data Collection

Child psychiatric assessment REQUIRES data from multiple sources because children's behavior varies across settings and children are unreliable self-reporters (especially under age 10):

• Parent/caregiver interview: Primary history source. Complete CBCL (Child Behavior Checklist, ages 1.5-5 or 6-18), Conners Parent Rating Scale, or disorder-specific measures.
• Teacher report: CBCL-TRF (Teacher Report Form) or Conners Teacher Rating Scale. Essential for ADHD, ODD, and learning difficulties.
• Child interview: Developmentally adapted. Use play, drawing, and age-appropriate language. The interview provides direct behavioral observation and the child's subjective experience.
• Pediatrician: Medical history, growth parameters, medication history.

---

Step 2: Child Mental Status Examination

The child MSE must be adapted for developmental level:

Preschool (3-5):

• Observe in play: Themes (aggression, nurturing, fear), ability to engage in pretend play, attention span, frustration tolerance
• Separation behavior: How child separates from parent, reunion behavior (attachment pattern)
• Language: Vocabulary, syntax, pragmatic language, echolalia
• Motor: Fine motor (drawing, block building), gross motor, coordination
• Affect regulation: Response to limits, transitions, frustration
• Social engagement: Eye contact, reciprocal interaction, interest in examiner

School-age (6-12):

• Standard MSE domains adapted for age
• Use structured interviews (K-SADS-PL — Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime version) for diagnostic assessment
• Assess academic self-concept, peer relationships, bullying (perpetrator and victim)
• Ask about suicidal ideation directly — children as young as 6 can have suicidal thoughts
• Assess screen time, social media use, gaming

Adolescent (13-17):

• Full adult MSE with developmental context
• Confidential portion of interview without parents present (essential for disclosure of substance use, sexual activity, self-harm, abuse, identity concerns)
• Assess: Substance use (CRAFFT screening tool), sexual activity, suicidal ideation (C-SSRS), self-harm, disordered eating, gender identity, sexual orientation, bullying/cyberbullying, social media impact
• HEADSS assessment: Home, Education, Activities, Drugs, Suicidality, Sex

---

Step 3: Diagnostic Considerations Specific to Pediatric Populations

Common diagnostic pitfalls:

• ADHD vs. anxiety: Inattention may be driven by worry, not ADHD. Comorbidity is common (30-40%).
• ADHD vs. trauma: Hyperarousal, concentration difficulty, and behavioral dysregulation from PTSD mimic ADHD. Screen for trauma exposure before diagnosing ADHD.
• ODD vs. mood disorder: Irritability is a core feature of both. DMDD (Disruptive Mood Dysregulation Disorder) was created for DSM-5 to address chronic irritability: severe recurrent temper outbursts ≥3x/week, irritable/angry mood most of the day nearly every day, for ≥12 months, in ≥2 settings, with onset before age 10.
• Autism Spectrum Disorder: Screen with M-CHAT-R/F (ages 16-30 months) or SCQ/SRS-2 (school-age). Key features: persistent deficits in social communication/interaction + restricted, repetitive patterns of behavior. Formal diagnosis requires comprehensive evaluation including ADOS-2.
• Pediatric bipolar disorder: Controversial. Distinguish from DMDD. Classic mania (grandiosity, decreased need for sleep, pressured speech, goal-directed activity) is rare before puberty. Do not diagnose bipolar solely based on irritability.
• Depression in children: May present as irritability rather than sadness. Somatic complaints (stomach aches, headaches) are common. Use CDI-2 (Children's Depression Inventory) for screening.

---

Step 4: Treatment Planning for Pediatric Patients

Psychotherapy (First-Line for Most Conditions)

• ADHD: Behavioral parent training (ages 4-5), school-based interventions, organizational skills training
• Anxiety disorders: CBT (Coping Cat program), exposure-based therapy. First-line per AACAP.
• Depression: CBT, IPT-A (Interpersonal Therapy for Adolescents). TADS study showed combination fluoxetine + CBT superior to either alone.
• ODD/Conduct Disorder: Parent Management Training (PMT), Multisystemic Therapy (MST), Functional Family Therapy (FFT)
• PTSD: Trauma-Focused CBT (TF-CBT) — gold standard for children and adolescents. EMDR also effective.
• ASD: Applied Behavior Analysis (ABA), social skills training, speech/language therapy, occupational therapy
• Eating disorders (adolescents): Family-Based Treatment (FBT/Maudsley) is first-line for AN

Pharmacotherapy Considerations

• FDA Black Box Warning: All antidepressants carry risk of increased suicidality in patients <25 — monitor weekly for first 4 weeks, biweekly for weeks 5-8, then as clinically indicated.
• ADHD: Methylphenidate and amphetamine formulations are first-line (FDA approved age 6+). Monitor height, weight, blood pressure, heart rate. Obtain cardiac history and ECG if family history of sudden death, cardiomyopathy, or arrhythmia.
• Depression: Fluoxetine (FDA approved age 8+) is first-line. Escitalopram (FDA approved age 12+) is second-line.
• Anxiety: SSRIs (fluoxetine, sertraline) are first-line. CAMS study showed sertraline + CBT most effective.
• Psychosis: Risperidone (FDA approved age 13+ for schizophrenia), aripiprazole (age 13+). Metabolic monitoring protocol required.
• Bipolar mania: Lithium (FDA approved age 12+), aripiprazole (age 10+), risperidone (age 10+), quetiapine (age 10+).
• Start at lower doses than adult, titrate slower, and monitor growth parameters.

---

Step 5: Family Integration, School Coordination, and Legal Considerations

Family involvement:

• Include parents/caregivers in treatment planning (required, not optional)
• Provide psychoeducation about diagnosis, treatment, and prognosis
• Address family dynamics contributing to or maintaining symptoms
• Screen parents for psychiatric conditions (parental depression, SUD, domestic violence)

School coordination:

• Provide documentation supporting 504 Plan or IEP eligibility
• Communicate with school counselor/psychologist (with appropriate releases)
• Recommend specific classroom accommodations

Legal and ethical considerations:

• Consent: Legal guardian provides informed consent; obtain assent from child (age 7+ per AACAP)
• Confidentiality in adolescents: Balance parent's right to information with adolescent's need for privacy. State laws vary on minor consent for mental health treatment (typically ages 12-16).
• Mandatory reporting: If child abuse or neglect is suspected, report to child protective services immediately. Document the report.
• Custody disputes: Avoid taking sides; document objectively; may need separate consent from both custodial parents depending on custody order.

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the developmental context documented for interpreting symptoms and behavior?
2. Are multi-informant data sources obtained and integrated (parent, teacher, child)?
3. Are diagnostic considerations specific to pediatric populations addressed (DMDD vs. bipolar, ADHD vs. trauma)?
4. Are treatment recommendations age-appropriate and aligned with AACAP Practice Parameters?
5. Are consent, assent, and mandatory reporting obligations documented?

---

Quality Audit

• Developmental history obtained including prenatal, birth, milestones
• Multi-informant assessment completed (parent, teacher, child)
• Standardized rating scales administered to parents and teachers
• Child MSE adapted for developmental level
• Diagnostic assessment considers developmental context and pediatric-specific differentials
• Trauma and abuse screening completed with mandatory reporting compliance
• Suicidal ideation assessed (even in young children)
• Treatment plan includes psychotherapy as first-line when indicated
• Medication recommendations include FDA approval status and Black Box Warning discussion
• Growth parameter monitoring plan documented for stimulants and antipsychotics
• Family involvement in treatment planning documented
• School coordination plan documented (IEP/504 recommendation if appropriate)
• Consent (guardian) and assent (child) documented
• Custody and legal considerations addressed

---

Guidelines

1. Never diagnose a child based on a single informant — multi-informant, multi-setting assessment is the standard of care per AACAP Practice Parameters.
2. Always screen for trauma exposure before diagnosing ADHD in children with behavioral dysregulation — trauma mimics ADHD and requires different treatment.
3. Monitor growth parameters (height and weight) in all children on stimulant medications — growth suppression is a documented side effect requiring periodic drug holidays or dose adjustment.
4. For adolescents, conduct a portion of the interview without parents present — adolescents will not disclose substance use, sexual activity, or self-harm with parents in the room.
5. Document the informed consent process with the legal guardian AND the assent process with the child — both are required for ethical pediatric practice.
6. Follow FDA Black Box Warning monitoring protocols for all antidepressants in patients under 25 — weekly contact for the first 4 weeks after initiation or dose change.
7. When prescribing off-label in pediatric patients, document the evidence base and rationale for the off-label use — off-label prescribing is common in child psychiatry but requires explicit justification.
8. Mandatory reporting of suspected child abuse or neglect is non-negotiable — the clinician's obligation to report supersedes therapeutic confidentiality.